Moonlake reports FY2022 net loss $64.5M; HS trial top-line expected June 2023

MoonLake Immunotherapeutics

Net loss for year ended Dec 31, 2022 was $64.5M vs $53.6M for prior period (March 2021 to Dec 2021).
Cash, equivalents and short-term marketable debt securities $72.1M at Dec 31, 2022; runway into 2H 2024.
Phase 2 HS trial top-line results expected around end of June 2023; final readout by Q4 2023.
Phase 2 PsA trial enrollment on schedule; top-line results anticipated at end of 2023.
Capital Markets Day set for April 19, 2023 in New York and via webcast.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MoonLake Immunotherapeutics reported the fourth quarter and year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $64.5 million.

Period: the fourth quarter and year ended December 31, 2022
Net income: Net loss for the year ended December 31, 2022 was $64.5 million
Result: reported results

Exact text from the filing

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

View on SEC.gov

Browse all earnings releases →

MoonLake Immunotherapeutics filing history →

Source: SEC EDGAR

accession 0001821586-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.